NOVO NORDISK A/S Under the programme initiated 3 February 2016, Novo Nordisk will repurchase B shares for an amount up to DKK 3.3 billion in the period from 3 February 2016 to 27 April 2016.
Since the announcement as of 1 April 2016, the following transactions have been made under the programme:
Number of B shares | Average purchase price | Transaction value, DKK | |
Accumulated, last announcement | 6,514,000 | 2,296,350,520 | |
1 April 2016 | 140,000 | 355.06 | 49,708,694 |
4 April 2016 | 150,000 | 365.64 | 54,846,285 |
5 April 2016 | 150,000 | 361.97 | 54,296,100 |
6 April 2016 | 150,000 | 365.34 | 54,800,505 |
7 April 2016 | 150,000 | 370.03 | 55,504,125 |
8 April 2016 | 150,000 | 367.36 | 55,103,430 |
Accumulated under the programme | 7,404,000 | 2,620,609,659 |
With the transactions stated above, Novo Nordisk owns a total of 59,562,645 B shares of DKK 0.20, corresponding to 2.3% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,600,000,000 including treasury shares.
Page 2 of 2
Novo Nordisk expects to repurchase B shares for an amount up to DKK 14 billion during a 12-month period beginning 3 February 2016. As of 8 April 2016, Novo Nordisk has repurchased a total of 7,404,000 B shares equal to a transaction value of DKK 2,620,609,659.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,000 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
Media: | ||
Anne Margrethe Hauge | +45 3079 3450 | amhg@novonordisk.com |
Investors: | ||
Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
Daniel Bohsen | +45 3079 6376 | dabo@novonordisk.com |
Melanie Raouzeos | +45 3075 3479 | mrz@novonordisk.com |
Kasper Veje | +45 3079 8519 | kpvj@novonordisk.com |
Novo Nordisk A/S issued this content on 11 April 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 11 April 2016 14:26:32 UTC
Original Document: http://www.novonordisk.com/bin/getPDF.2002411.pdf
